4.3 Article

Non-invasive diagnosis and follow-up of primary malignant liver tumours

Publisher

ELSEVIER MASSON, CORP OFF
DOI: 10.1016/j.clinre.2021.101766

Keywords

Hepatocellular carcinoma; Cirrhosis; Imaging; Non-invasive; Screening

Ask authors/readers for more resources

Hepatocellular carcinoma (HCC) is the most common malignant liver tumor that develops on a background of cirrhosis, and histological confirmation is not mandatory in many cases due to typical radiological patterns described by contrast-enhanced imaging. Liver biopsy may be essential in atypical presentations or to exclude other rare malignant tumors developed in the absence of cirrhosis.
Among a wide range of malignant liver tumours, hepatocellular carcinoma (HCC) developed on a background of cirrhosis represents the most frequent clinical situation. In this setting, HCC is one of the rare solid tumours for which histological confirmation is not mandatory. The convergence of multiple arguments obtained by non-invasive parameters using radiological findings allows to avoid liver biopsy in a large proportion of patients when a diagnosis of underlying cirrhosis is ascertained. Conversely, in case of atypical presentation or in order to exclude other rare malignant tumours mostly developed in the absence of cirrhosis, liver biopsy will then be essential. Based on typical radiological patterns described by contrast-enhanced imaging, numerous clinical guidelines have endorsed non-invasive diagnosis, staging and monitoring of HCC patients under treatment since 20 years. These algorithms have evolved over the years, taking into account progress in radiological technology and advances in curative or palliative procedures. Large cohort studies have also helped to refine diagnostic criteria and prognostication in the setting of complex therapeutic strategy. Unsupervised multi-analysis approaches both at the biological and radiological levels will in the future enrich the panel of non-invasive markers useful in clinical practice to manage HCC and other malignant tumours. (C) 2021 Published by Elsevier Masson SAS.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available